Sangamo Therapeutics

SGMO48

Penny Stock

$0.72arrow_drop_down4.00%-$0.03

Penny Stock

SGMO48

$0.72

arrow_drop_down4.00%-$0.03

Penny Stock

Performance History

Key Stats
Open	$0.79
Prev. Close	$0.80
EPS	-1.38
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$170.53M
PE Ratio	-

	LOW	HIGH
Day Range	0.72	0.80
52 Week Range	0.29	1.48

Ratios

Revenue	-





EPS	-1.38

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Sangamo Therapeutics (SGMO)

Sangamo Therapeutics Inc (SGMO) is a California-based biotechnology company specializing in genome editing. The company utilizes its proprietary zinc finger nuclease (ZFN) technology to develop genomic therapies for a wide range of diseases. With a market capitalization of [Sangamo Therapeutics Inc, SGMO market cap], Sangamo Therapeutics is a key player in the biotech industry. The company's [Sangamo Therapeutics Inc, SGMO stock price history] has experienced fluctuations over the years, influenced by various factors such as clinical trial results, partnerships, and market trends. It is important for investors to keep an eye on these developments when considering investing in Sangamo Therapeutics.

Sangamo Therapeutics Inc's focus on genomic therapies positions it at the forefront of the industry. The company's expertise in genome editing provides promising opportunities for treating genetic diseases that were previously considered untreatable. Sangamo Therapeutics has made significant progress in clinical trials, demonstrating the potential of its therapies in conditions like HIV, hemophilia, and cancer. The company's innovative approach sets it apart from its competitors, giving it a competitive edge in the market.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
Headquarters: Brisbane
Employees: 478
Exchange: NASDAQ

Keep an eye on Sangamo Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Sangamo Therapeutics 's (SGMO) price per share?

The current price per share for Sangamo Therapeutics (SGMO) is $0.72. The stock has seen a price change of -$0.03 recently, indicating a -4% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Sangamo Therapeutics (SGMO)?

For Sangamo Therapeutics (SGMO), the 52-week high is $1.48, which is 105.56% from the current price. The 52-week low is $0.29, the current price is 148.28% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Sangamo Therapeutics (SGMO) a growth stock?

Sangamo Therapeutics (SGMO) has shown an average price growth of 0.41% over the past three years. It has received a score of 0 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Sangamo Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Sangamo Therapeutics (SGMO) stock price performance year to date (YTD)?

As of the latest data, Sangamo Therapeutics (SGMO) has a year-to-date price change of 29.43%. Over the past month, the stock has experienced a price change of -27.29%. Over the last three months, the change has been 21.68%. Over the past six months, the figure is -28.71%. Looking at a longer horizon, the five-year price change stands at -93.22%.

help

Is Sangamo Therapeutics (SGMO) a profitable company?

Sangamo Therapeutics (SGMO) has a net income of -$257.83M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 87.41% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -9.41K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 58.34%, providing insight into the company's sales performance and growth. The gross profit is $154.04M. Operating income is noted at -$114.29M. Furthermore, the EBITDA is $58.21M.

help

What is the market capitalization of Sangamo Therapeutics (SGMO)?

Sangamo Therapeutics (SGMO) has a market capitalization of $156.26M. The average daily trading volume is 3.78M, indicating the stock's liquidity and investor engagement.

News

Gene Therapy Market Size to Reach USD 54.39 Billion By 2032 with CAGR of 23.12%, Boosted by Rising Genetic Disorders and Advances in CRISPR Technology